Processa Pharmaceuticals Announces Key Leadership Appointments

Processa Pharmaceuticals announced key leadership appointments including Gregory J. Flesher as Chief Operating Officer, Craig Coburn as EVP Head of Research, Ashley Hall as EVP Development, and Michael P. Cruse as EVP Business Operations. These appointments follow the company's July 2026 acquisition of Vidya Therapeutics and $200 million financing. The company is advancing VT-7208, a next-generation BTK inhibitor, across Phase 2 studies in food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis, with FDA clearance recently received for the CSU study.